The proteasome inhibitor bortezomib is used for multiple myeloma treatment, but drug resistance commonly develops. Dharminder Chauhan, Kenneth Anderson and colleagues reasoned that, rather than broadly inhibiting proteolysis, enhancing the proteolysis of particular oncogenes may be an alternative therapeutic strategy. They identified an inhibitor (P5091) of ubiquitin-specific protease 7 (USP7) that blocked MDM2 deubiquitylation by USP7 and thus stabilized p53. P5091 caused apoptosis and overcame bortezomib resistance in multiple myeloma cells in vitro and also slowed the growth of various multiple myeloma xenografts in mice.
ORIGINAL RESEARCH PAPER
Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345–358 (2012)
Rights and permissions
About this article
Cite this article
Burgess, D. Dual-pronged proteasomal promise?. Nat Rev Cancer 12, 659 (2012). https://doi.org/10.1038/nrc3378
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3378